Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine
January 30 2025 - 4:38PM
A groundbreaking precision medicine system developed by biotech
trailblazer Diag-Nose.io hopes to transform the management of
chronic respiratory diseases worldwide after closing its
oversubscribed seed round this week.
CDL-Seattle Alumni, Diag-Nose.io Team, Celebrates
Breakthrough in AI-Driven Respiratory Care
A graduate of Creative Destruction Lab’s 2023 class for Digital
Health in Seattle, Diag-Nose.io is pioneering advancements in
respiratory healthcare by focusing on the “unified airway”: the
biological relationship between the lungs and nasal passages.
Traditional diagnostic methods for chronic respiratory
conditions - such as asthma and chronic obstructive pulmonary
disorder (COPD) and chronic sinusitis - rely on outdated
measurement tools and subjective assessments. This approach
contributes to treatment failure in over 30% of patients, incurring
significant costs and delaying effective care.
Diag-Nose.io’s revolutionary RhinoMAP™ platform combines machine
learning (artificial intelligence) with advanced proteomics to
enable precision-matched treatments based on each patient’s unique
biological profile, or “endotype.”
ABEL Microsampler™
The system leverages patented nasal liquid biopsy technology,
the ABEL Microsampler™, to collect nasal fluid samples for
comprehensive biomarker analysis. These insights intend to guide
care by identifying disease progression, therapeutic
responsiveness, and optimal treatment pathways.“Over 40 million
Americans suffer from chronic respiratory conditions, and globally,
these diseases affect more than 450 million people, causing
approximately four million deaths in 2019,” said Eldin Rostom, CEO
and Co-Founder of Diag-Nose.io. “Together with the new biologics
medicines, our RhinoMAP™ system will bring us one step closer
towards the holy grail of respiratory medicine; helping patients
become completely free of symptoms. This progress is made possible
through the unwavering support and investment from visionary
partners who share our mission, as well as the transformative
support of the Creative Destruction Lab program at the University
of Washington, which inspired us to think bigger and exponentially
accelerated our commercialization pathway.”The oversubscribed $2
million round was led by Breakthrough Victoria, with additional
investments from Radar Ventures, a syndicate of physicians from
Specialty Physician Associates (SPA), biotech angel investors Carl
Stubbings, Stephen Ho, and Richard Lipscombe, as well as physicians
affiliated with leading U.S. hospitals. Carl Stubbings will join
Diag-Nose.io’s board as Chairperson.Emer Dooley, Site Lead at
CDL-Seattle, endorsed Diag-Nose.io’s achievements,
stating:“Diag-Nose.io exemplifies the transformative innovation we
strive to cultivate at CDL-Seattle. Their AI-driven approach to
precision medicine and commitment to addressing chronic respiratory
diseases underscores the profound impact deep-tech startups can
achieve. We are proud to have supported their journey and look
forward to their continued advancements in respiratory
healthcare.”
Diag-Nose.io plans to launch a series of clinical studies across
the United States in 2025 to further validate its technology and
invites interested academic and industry partners to collaborate in
driving forward this revolutionary approach to respiratory and
rhinology care.
MEDIA CONTACT
For any questions in relation to this release or to discuss
interviews, please contact:
Nicole Papoutsis
media@diag-nose.io
About Diag-Nose.io
Diag-Nose.io, founded in 2020, is a biotechnology company
focused on translating the complexities of the unified airway into
precision diagnostic and drug discovery solutions.
Their precision medicine technology combines advanced
proteomics, computational biology, and AI (machine learning) to
create a scalable respiratory biology model. This innovation aims
to help clinicians prescribe the right treatments faster and enable
researchers to accelerate the development of new therapies.
The company’s flagship platform, RhinoMAP™, leverages proteomic
data to predict respiratory disease activity, monitor therapy
response and predict treatment efficacy in advance, with an initial
focus on anti-Th2 biologics.
website: https://diag-nose.io/
Disclaimer:The RhinoMAP platform, ABEL
microsampler™, RhinoMAP™ and any associated technologies or
products developed by Diag-Nose.io have not been evaluated by the
U.S. Food and Drug Administration (FDA) and are not currently
approved for diagnostic or therapeutic use.
This press release is for informational purposes
only and should not be interpreted as medical advice. Consult a
qualified healthcare professional for medical guidance.
This announcement does not constitute an offer
to sell, or a solicitation of an offer to buy, securities in the
United States or any other jurisdiction. Any securities described
in this announcement have not been, and will not be, registered
under the US Securities Act of 1933 and may not be offered or sold
in the United States except in transactions exempt from, or not
subject to, the registration of the US Securities Act and
applicable US state securities laws.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a771f6b6-7980-4a1e-9b74-61d38afe5da7
https://www.globenewswire.com/NewsRoom/AttachmentNg/35f53039-3be9-4985-9670-5d65e661ba4d